Premier Biomedical Inc (BIEI) Financial Statements (2024 and earlier)
Company Profile
| Business Address |
P.O. BOX 25 JACKSON CENTER, PA 16133 |
| State of Incorp. | NV |
| Fiscal Year End | December 31 |
| Industry (SIC) | 2836 - Biological Products, Except Diagnostic Substances (benchmarking) |
| More info | Complete Financial Analysis Financial Benchmarking |
Balance Sheet (Statement of Financial Position) ($ in thousands)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | |||
|---|---|---|---|---|---|---|---|---|---|
| ASSETS | |||||||||
| Current Assets | |||||||||
| Cash, cash equivalents, and short-term investments | 87 | 84 | 22 | 35 | 103 | 16 | |||
| Cash and cash equivalents | 87 | 84 | 22 | 35 | 103 | 16 | |||
| Receivables | 3 | 0 | 37 | ||||||
| Inventory, net of allowances, customer advances and progress billings | 26 | 85 | ✕ | ||||||
| Inventory | 26 | 85 | |||||||
| Prepaid expense | 11 | 9 | 9 | 6 | |||||
| Other current assets | 44 | 35 | |||||||
| Other undisclosed current assets | (16) | 3 | |||||||
| Total current assets: | 160 | 204 | 34 | 67 | 116 | 22 | |||
| Noncurrent Assets | |||||||||
| Property, plant and equipment | 5 | 5 | 5 | 4 | 5 | 4 | |||
| Total noncurrent assets: | 5 | 5 | 5 | 4 | 5 | 4 | |||
| TOTAL ASSETS: | 165 | 209 | 39 | 70 | 121 | 25 | |||
| LIABILITIES AND EQUITY | |||||||||
| Liabilities | |||||||||
| Current Liabilities | |||||||||
| Accounts payable and accrued liabilities | 286 | 353 | 239 | 196 | 147 | 122 | |||
| Interest and dividends payable | 22 | 6 | 18 | 8 | |||||
| Accounts payable | 264 | 347 | 221 | 188 | 147 | 122 | |||
| Debt | 310 | 170 | 30 | 30 | 15 | 109 | |||
| Due to related parties | 26 | 41 | 82 | 85 | |||||
| Other undisclosed current liabilities | 1,690 | 2,256 | 348 | 36 | 26 | 43 | |||
| Total current liabilities: | 2,312 | 2,820 | 700 | 347 | 188 | 275 | |||
| Noncurrent Liabilities | |||||||||
| Total liabilities: | 2,312 | 2,820 | 700 | 347 | 188 | 275 | |||
| Equity | |||||||||
| Equity, attributable to parent, including: | (2,147) | (2,611) | (661) | (276) | (68) | (249) | |||
| Preferred stock | 2 | 2 | 2 | ||||||
| Common stock | 0 | 6 | 3 | 1 | 0 | 0 | |||
| Additional paid in capital | 14,573 | 13,436 | 11,900 | 10,501 | 8,128 | 6,536 | |||
| Accumulated deficit | (16,728) | (16,329) | (12,565) | (10,778) | (8,196) | (6,785) | |||
| Other undisclosed equity, attributable to parent | 5 | 274 | |||||||
| Total equity: | (2,147) | (2,611) | (661) | (276) | (68) | (249) | |||
| TOTAL LIABILITIES AND EQUITY: | 165 | 209 | 39 | 70 | 121 | 25 | |||
Income Statement (P&L) ($ in thousands)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Revenues | 40 | 40 | 10 | |||||
| Net investment income | 10 | |||||||
| Cost of revenue | (114) | (25) | ||||||
| Cost of goods and services sold | (88) | (25) | ||||||
| Gross profit: | (74) | 14 | 10 | |||||
| Operating expenses | (619) | (1,304) | (638) | (2,383) | (1,369) | (4,477) | ||
| Other undisclosed operating loss | (10) | |||||||
| Operating loss: | (693) | (1,290) | (638) | (2,383) | (1,369) | (4,477) | ||
| Nonoperating income (expense) | 294 | (2,474) | (1,130) | (199) | (42) | (400) | ||
| Interest and debt expense | (415) | (352) | (817) | (199) | (42) | (400) | ||
| Loss from continuing operations: | (814) | (4,115) | (2,586) | (2,781) | (1,452) | (5,278) | ||
| Loss before gain (loss) on sale of properties: | (814) | (4,115) | (2,586) | (2,781) | (1,452) | (5,278) | ||
| Other undisclosed net income | 199 | 42 | 400 | |||||
| Net loss: | (814) | (4,115) | (2,586) | (2,582) | (1,411) | (4,877) | ||
| Other undisclosed net income attributable to parent | 415 | 352 | 817 | |||||
| Net loss available to common stockholders, diluted: | (399) | (3,764) | (1,768) | (2,582) | (1,411) | (4,877) | ||
Comprehensive Income ($ in thousands)
| 12/31/2019 | 12/31/2018 | 12/31/2017 | 12/31/2016 | 12/31/2015 | 12/31/2014 | 12/31/2013 | ||
|---|---|---|---|---|---|---|---|---|
| Net loss: | (814) | (4,115) | (2,586) | (2,582) | (1,411) | (4,877) | ||
| Comprehensive loss, net of tax, attributable to parent: | (814) | (4,115) | (2,586) | (2,582) | (1,411) | (4,877) | ||
Statements Sources
The financial statements are based on the Company's filings with the U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.